Novo Nordisk A/S
Novo Nordisk A/S (NVO) Revenue
Annual & quarterly revenue history · segment & region breakdown
NVO · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsNovo Nordisk A/S trailing twelve-month (TTM) revenue is $328B, an increase of 6.43% year-over-year from $309B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $309B | +$18.66B | +6.43% |
| 2024-12-31 | $290B | +$58.14B | +25.03% |
| 2023-12-31 | $232B | +$55.31B | +31.26% |
| 2022-12-31 | $177B | +$36.15B | +25.68% |
| 2021-12-31 | $141B | +$13.85B | +10.91% |
| 2020-12-31 | $127B | +$4.92B | +4.04% |
| 2019-12-31 | $122B | +$10.19B | +9.11% |
| 2018-12-31 | $112B | +$0.14B | +0.12% |
| 2017-12-31 | $112B | -$0.08B | -0.08% |
| 2016-12-31 | $112B | +$3.85B | +3.57% |
Compare revenue vs peers
BiotechnologyCompare NVO revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Novo Nordisk A/S receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Novo Nordisk A/S reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in DKK.
Data sourced from Novo Nordisk A/S's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
NVO revenue · 4 questionsNVO's trailing twelve-month (TTM) revenue is $328B. That is an increase of 6.43% year-over-year from $309B in FY2025.
▸ Source: FMP · Novo Nordisk A/S SEC filings · GAAP · Novo Nordisk A/S SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026